ES2316553T3 - Analogos de lipoxina como nuevos inhibidores de la angiogenesis. - Google Patents

Analogos de lipoxina como nuevos inhibidores de la angiogenesis. Download PDF

Info

Publication number
ES2316553T3
ES2316553T3 ES02721234T ES02721234T ES2316553T3 ES 2316553 T3 ES2316553 T3 ES 2316553T3 ES 02721234 T ES02721234 T ES 02721234T ES 02721234 T ES02721234 T ES 02721234T ES 2316553 T3 ES2316553 T3 ES 2316553T3
Authority
ES
Spain
Prior art keywords
baselineskip
inclusive
atoms
carbon atoms
branched chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02721234T
Other languages
English (en)
Spanish (es)
Inventor
Charles N. Serhan
Iolanda M. Fierro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Application granted granted Critical
Publication of ES2316553T3 publication Critical patent/ES2316553T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02721234T 2001-03-02 2002-03-01 Analogos de lipoxina como nuevos inhibidores de la angiogenesis. Expired - Lifetime ES2316553T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27293101P 2001-03-02 2001-03-02
US272931P 2001-03-02
US86609 2002-03-01
US10/086,609 US6627658B2 (en) 2001-03-02 2002-03-01 Lipoxin analogs as novel inhibitors of angiogenesis

Publications (1)

Publication Number Publication Date
ES2316553T3 true ES2316553T3 (es) 2009-04-16

Family

ID=26774943

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02721234T Expired - Lifetime ES2316553T3 (es) 2001-03-02 2002-03-01 Analogos de lipoxina como nuevos inhibidores de la angiogenesis.

Country Status (11)

Country Link
US (4) US6627658B2 (enExample)
EP (2) EP1406698B1 (enExample)
JP (3) JP2005508282A (enExample)
AT (1) ATE412448T1 (enExample)
AU (1) AU2002252175A1 (enExample)
CY (1) CY1108670T1 (enExample)
DE (1) DE60229640D1 (enExample)
DK (1) DK1406698T3 (enExample)
ES (1) ES2316553T3 (enExample)
PT (1) PT1406698E (enExample)
WO (1) WO2002070068A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
EP1268393A2 (en) * 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
EP1406698B1 (en) * 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) * 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
ZA200703992B (en) * 2004-11-09 2009-08-26 Alcon Inc 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
EP2012828A2 (en) * 2006-04-28 2009-01-14 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
BRPI0714562A2 (pt) * 2006-07-19 2013-04-02 Resolvyx Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de mucosites
EP2131833A2 (en) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
EA018175B1 (ru) * 2007-08-08 2013-06-28 Басф Се Водные микроэмульсии, содержащие органические инсектицидные соединения
EP2207543A2 (en) * 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
EP2219638A2 (en) * 2007-10-29 2010-08-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Lipoxin a4 protection for retinal cells
US7601693B2 (en) * 2008-02-05 2009-10-13 National Taiwan University Composition for treating cancer and use thereof
US20100105772A1 (en) * 2008-04-25 2010-04-29 Serhan Charles N Use of novel lipid mediators to inhibit angiogenesis
WO2014130908A1 (en) * 2013-02-22 2014-08-28 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
CN105408472A (zh) 2013-03-15 2016-03-16 马卡斯凯尔·托莱夫·拉尔森 用于脐带血收集及细胞分离的细胞、方法和装置
EP3020398A1 (en) * 2014-11-17 2016-05-18 Nitto Denko Corporation Compounds and formulations for reducing scarring
KR102437682B1 (ko) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
US11519911B2 (en) 2017-01-31 2022-12-06 The Brigham And Women's Hospital, Inc. ALX receptor ligands define a biochemical endotype for inflammation-based diseases
US11439615B2 (en) * 2017-03-09 2022-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2020256628A1 (en) 2019-06-20 2020-12-24 Amniotics Ab An apparatus for filtering amniotic fluid
JP7714535B2 (ja) 2019-10-18 2025-07-29 アムニオティクス・アーベー 羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
KR20240150603A (ko) 2022-03-03 2024-10-15 테티스 파마수티컬스 엘엘씨 특수화된 해소촉진 매개체의 시클로덱스트린 복합체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en) 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
EP0703897B1 (en) * 1993-06-15 2008-08-20 The Brigham And Women's Hospital, Inc. Lipoxin compounds with prolonged half-life
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US5750354A (en) 1994-03-11 1998-05-12 Brigham And Women's Hospital Lipoxin transport system and uses therefor
US6365712B1 (en) * 1996-10-25 2002-04-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
ES2246230T3 (es) * 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
IL151299A0 (en) * 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
EP1268393A2 (en) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
EP1406698B1 (en) 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis

Also Published As

Publication number Publication date
US20020193431A1 (en) 2002-12-19
JP2012255025A (ja) 2012-12-27
US20060009521A1 (en) 2006-01-12
US20080064749A1 (en) 2008-03-13
DK1406698T3 (da) 2009-02-09
CY1108670T1 (el) 2014-04-09
DE60229640D1 (de) 2008-12-11
WO2002070068A2 (en) 2002-09-12
WO2002070068A3 (en) 2003-12-31
EP1406698A2 (en) 2004-04-14
JP5302856B2 (ja) 2013-10-02
US8008282B2 (en) 2011-08-30
EP2221089A1 (en) 2010-08-25
JP2005508282A (ja) 2005-03-31
US6627658B2 (en) 2003-09-30
ATE412448T1 (de) 2008-11-15
US20040053998A1 (en) 2004-03-18
PT1406698E (pt) 2009-01-12
AU2002252175A1 (en) 2002-09-19
JP2010059183A (ja) 2010-03-18
EP1406698B1 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
US8008282B2 (en) Lipoxin analogs as novel inhibitors of angiogenesis
Fierro et al. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15 R-lipoxin A4 and lipoxin A4
US6255347B1 (en) Methods and compositions comprising R-ibuprofen
ES2344138T3 (es) Analogos de 16-fenoxi-lipoxina para utilizacion medica.
WO1997048391A9 (en) Methods and compositions comprising r-ibuprofen
CN107106580B (zh) 治疗癌症干细胞的组合物
JP2001518935A (ja) 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体
KR100861428B1 (ko) 암 치료용 지방산 유사체
TW201039815A (en) Compositions and methods for the treatment of inflammation
JP2006117691A (ja) グラム陰性感染に対する細胞防御を促進するためのリポキシンアナログの使用
WO2009099553A2 (en) Use of kinase inhibitor in treatment of atherosclerosis
Mollinedo et al. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
JP5289310B2 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
PT2120919E (pt) Nova combinação para utilização no tratamento de perturbações inflamatórias
ES2344814T3 (es) Analogos de lipoxina como nuevos inhibidores de la angiogenesis.
CN105682660A (zh) 通过与亲脂性他汀类药物的组合使用加强甲氨蝶呤的作用
CN101014330A (zh) 2,5－二羟基苯磺酸在制备可应用于治疗血管依赖型疾病诸如癌症和银屑病的药物中的应用
WO2003043663A1 (fr) Preparations inhibant le rejet dans la transplantation d'organe et son procede d'utilisation
US8722654B2 (en) Lipoxin analogs as novel inhibitors of angiogenesis
WO2018137701A1 (zh) 靶向cxcr7的药物组合物和方法
HK1118744B (en) Lipoxin analogs as novel inhibitors of restenosis
CN114340672A (zh) 包含hdac抑制剂和抗pd1抗体或抗pd-l1抗体的药物组合物
JPH06501024A (ja) 皮膚腫瘍形成を予防し、存在する腫瘍の後退の原因になるための医薬組成物と方法
JP3981739B2 (ja) 抗癌剤、癌細胞の増殖を抑制する方法